EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer
This trial is active, not recruiting.
|Conditions||esophageal cancer, stomach cancer, pancreatic cancer|
|Treatments||standard follow-up, pet/ct and eus|
|Sponsor||Michael Bau Mortensen|
|Collaborator||Odense University Hospital|
|Start date||April 2011|
|End date||January 2016|
|Trial size||182 participants|
|Trial identifier||NCT02209415, 2011-41-5702|
Follow-up after successful operative treatment of cancer in the esophagus, stomach or pancreas in order to detect recurrent disease is a controversial topic.
This is because the methods and the consequence of following these patients is unknown.
Therefore the investigators will randomize these patients in to two groups:
1. One group of patients will be offered visits with a specialist surgeon in a outpatient setting for a clinical evaluation every 3,6,9,12,18 and 24 months after surgery, as is the current standard at our department.
2. The other group will be offered Endoscopic UltraSound, EUS, and PET/CT with the same intervals as the first group.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
Number of patients eligible for treatment
time frame: 2 years
Male or female participants at least 18 years old.
Inclusion Criteria: - R0- resection for primary adenocarcinoma or squamous cell carcinoma of the esophagus, stomach or pancreas.
|Official title||Endoscopic Ultrasound (EUS) and PET-CT Based Follow-up of Patients Radically Resected for Cancer of the Oesophagus, Stomach or Pancreas.|
Call for more information